SEC Form 4 · accession 0001013606-18-000012
ENDOLOGIX INC /DE/ · ELGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vaseem Mahboob
Officer — Chief Financial Officer
Period of report
Feb 7, 2018
Accepted (ET)
Feb 9, 2018 · 5:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001013606
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Feb 7, 2018 | A | 33,201 | $0.00 | A | 149,444 | D | |
| Common SharesF2 | Feb 7, 2018 | F | 4,632 | $4.05 | D | 144,812 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This award was originally reported on a Form 4 filed with the Securities and Exchange Commission on February 17, 2016. 33% of the shares subject to this restricted stock award vested pursuant the terms of this award.
- F2Shares sold on February 7, 2018 to satisfy statutory minimum tax withholding obligations related to shares vested on February 4, 2018.